Skip to main content
. 2022 Jul 28;12:898233. doi: 10.3389/fonc.2022.898233

Table 1.

Baseline characteristics of patients.

characteristics BEFORE PSM a AFTER PSM a
No TRA (N=63)(%) TRA (N=89)(%) P No TRA (N=57)(%) TRA (N=57)(%) P
Age (years)
 <65 36 (57.1) 56 (62.9) 0.473 35 (61.4) 35 (61.4) 1
 ≥65 27 (42.9) 33 (37.1) 22 (38.6) 22 (38.6)
Gender
 Male 44 (69.8) 76 (85.4) 0.021 44 (77.1) 44 (77.1) 1
 Famale 19 (30.2) 13 (14.7) 13 (22.9) 13 (22.9)
Smoking
 No 33 (52.4) 62 (69.7) 0.03 29 (50.9) 38 (66.7) 0.087
 Yes 30 (47.6) 27 (30.3) 28 (49.1) 19 (33.3)
Pathological pattern
 squamous carcinoma 35 (55.6) 71 (79.8) 0.005 34 (59.6) 43 (75.4) 0.184
 adenocarcinoma 18 (28.6) 13 (14.7) 15 (26.3) 10 (17.5)
 else 10 (15.9) 5 (5.6) 8 (14.1) 4 (7.1)
Weight loss
 <5% 39 (61.9) 67 (75.3) 0.077 37 (64.9) 46 (80.7) 0.058
 ≥5% 24 (38.1) 22 (24.7) 20 (35.1) 11 (19.3)
KPS
 >80 58 (92.1) 84 (94.4) 0.57 53 (93) 53 (93) 1 b
 ≤80 5 (7.9) 5 (5.6) 4 (7) 4 (7)
T classification
 T1-2 19 (30.2) 18 (20.2) 0.16 17 (29.8) 14 (24.6) 0.528
 T3-4 44 (69.8) 71 (79.8) 40 (70.2) 43 (75.4)
N classification
 N0-1 13 (20.6) 23 (25.8) 0.457 12 (21.1) 15 (26.3) 0.509
 N2-3 50 (79.4) 66 (74.2) 45 (78.9) 42 (73.7)
Stages
 IIb 6 (9.5) 9 (10.1) 0.159 5 (8.8) 6 (10.5) 0.233
 IIIa 14 (22.2) 15 (23.8) 13 (22.8) 10 (17.5)
 IIIb 23 (36.5) 35 (55.6) 21 (36.8) 19 (33.3)
 IIIc 13 (20.6) 9 (14.3) 11 (19.3) 6 (10.5)
 IV 7 (11.1) 21 (23.6) 7 (12.3) 16 (28.1)
Chemotherapy
 No 28 (44.4) 28 (31.5) 0.102 26 (45.6) 18 (31.6) 0.124
 Yes 35 (55.6) 61 (68.5) 31 (54.4) 39 (38.4)
a

aThe PSM was performed using age, sex, which were subdivided according to the median values.

b

.Fourfold table: sample size ≥ 40, 1 ≤ at least 2 theoretical frequencies < 5, using Fisher’s exact test;

n, number of cases/controls; PSM, propensity score matching.